Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 76,962,544.89
    Countries
    Sector(s)
    France : € 76,962,544.89
    Industry : € 76,962,544.89
    Signature date(s)
    25/07/2017 : € 76,962,544.89

    Summary sheet

    Release date
    11 May 2017
    Status
    Reference
    Signed | 25/07/2017
    20170188
    Project name
    Promoter - financial intermediary
    FRENCH ANIMAL HEALTH R&D INVESTMENTS
    VIRBAC SA
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 77 million
    EUR 250 million
    Location
    Sector(s)
    Description
    Objectives

    Investment to support research and development (R&D) for a robust portfolio of next-generation innovative products, addressing global animal health issues, to support Virbac's organic growth and international expansion. The project will be largely coordinated and implemented at the company's French R&D sites.

    The project will support the long-term innovation-driven organic growth of the company while enlarging its product portfolio, strengthening its competitive edge and scaling up market share as global player.

    Environmental aspects
    Procurement

    All project activities are expected to be carried out in existing facilities and laboratories without changing their already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU, as amended. Nevertheless, the Bank's services will review during the project appraisal whether any of the investments requires an EIA, as well as any other environmental details of the project.

    The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - FRENCH ANIMAL HEALTH R&D INVESTMENTS
    Publication Date
    12 Sep 2017
    Document language
    Main Topic
    Lending
    Document Number
    76124015
    Document Focus
    Environmental Information
    Project Number
    20170188
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications